רווח תפעולי לפני פחת: VolitionRx Limited (VNRX)

VolitionRx Limited (VNRX) develops epigenetic blood tests for humans and animals, reducing implementation risks. The baseline EBITDA reflects cash flow dynamics, where the value of 0.00 represents the most recent figure. However, the company faces a liquidity shortage due to high R&D expenditures. Business development is driven by leading epigenetic scientists from the US and Belgium who possess strong financial incentives.

This indicator reflects the net cash flow from operating activities before deducting tax and interest obligations, measuring the business's actual ability to generate liquidity. For VolitionRx Limited (VNRX), this metric confirms the effectiveness of integrating cancer tests into annual screenings, while the operating profit summary allows for an assessment of the sustainability of high-margin revenues and a timely adjustment of the asset's portfolio weighting.